1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025

EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025

  • August 2016
  • 79 pages
  • ID: 1957646
In this report:
Krumholz and colleagues, using national Medicare data for patients ages ≥## years, noted a decrease in the rate of hospitalizations of ##.##% and ##% for MI and UA, respectively, over the ##year period from 1998-2011 (Krumholz et al., 2009).
They demonstrated a negative ##.##% AGR in the incidence of heart disease from 1996-2005 and a negative ##.##% APC for all-cause mortality during the same time period.

Summary

Table of Contents

Search Inside

EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025

Brief

Acute coronary syndrome is a serious cardiovascular disease combined with high healthcare costs, frequent recurrences and hospitalizations, and high risks of sudden death and short-term mortality. The ACS incidence increases with age and will be a meaningful public health problem as the elderly population increases around the globe.

ACS is an umbrella term that describes conditions in which blood flow to the heart is blocked or reduced due to atherosclerotic plaques composed of white blood cells, cholesterol, and fat. ACS is classified into three disease entities established on evidence of heart muscle damage inferred from a person's symptoms, changes in the ST tracing of the electrocardiogram, and levels of cardiac biomarkers that signify heart muscle death.

Epidemiologists forecast that in the 7MM, the diagnosed prevalent cases of ACS will grow from 25.45 Million cases in 2015 to 30.62 Million cases in 2025, at an Annual Growth Rate of ~2.0 percent. Throughout the forecast period, the diagnosed prevalent cases of ACS in the U.S. will constitute the more significant proportion in the 7MM at approximately 54%.

In the 7MM, the diagnosed prevalent cases of ACS will be bigger in men (~61.8 percent) and in the age group older than 65 years (~62.8 percent). STEMI, NSTEMI, and UA will constitute approximately 25.0 percent, 40.0 percent, and 35.0 percent of the diagnosed prevalent cases of ACS in the 7MM.

In the 7MM, epidemiologists project ACS hospitalizations to increase from 1.63 Million cases in 2015 to 1.71 Million cases in 2025 at an AGR of ~0.5 percent. The U.S. constitutes around 40.0 percent of the global hospitalized ACS cases in the 7MM for the year 2015 and will be the sector with the more important number of cases during the forecast period. In 2015, the majority of the ACS hospitalizations occurred in men (~62.8 percent) and in the age group older than 65 years (~69.3 percent).

The market research "EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025" offers an overview of the risk factors, comorbidities, and the overall and historical trends for ACS in the seven main markets (7MM) (US, France (FR), Germany (DE), Italy (IT), Spain (ES), UK, and Japan (JP)). It includes a 10-year epidemiological forecast from 2015-2025 for the diagnosed prevalent cases of ACS, broken down by sex, age (in 10 year age groups from ages =25 years), and ACS type (STEMI, NSTEMI, and UA), and a 10-year epidemiological forecast for ACS hospitalizations, split by sex and ACS type (STEMI, NSTEMI, and UA).

Overview

- The Acute coronary syndrome EpiCast Report offers an overview of the risk factors, comorbidities, and the overall and historical trends for ACS in the seven main markets (7MM) (US, France (FR), Germany (DE), Italy (IT), Spain (ES), UK, and Japan (JP)). It includes a 10-year epidemiological forecast from 2015-2025 for the diagnosed prevalent cases of ACS, divided by sex, age (in 10 year age groups from ages =25 years), and ACS type (STEMI, NSTEMI, and UA), and a 10-year epidemiological forecast for ACS hospitalizations, broken down by sex and ACS type (STEMI, NSTEMI, and UA).

- The ACS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is detailed, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Great reasons to purchase

The ACS EpiCast report will allow you to -

- Develop strategic management by understanding the trends shaping and driving the overall ACS market.

- Quantify patient populations in the overall ACS market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for ACS therapeutics in each of the markets covered.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Amrita helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Hysteroscopy Instruments Market by Product, Resectoscope, Usability, Application, End User - Global Forecast to 2022

Hysteroscopy Instruments Market: Global Forecast until 2022

  • $ 5650
  • Industry report
  • October 2017
  • by MarketsandMarkets

“Global hysteroscopy instruments market projected to grow at a CAGR of 7.8%”The hysteroscopy instruments market is expected to reach USD 1.89 billion by 2022 from USD 1.30 billion in 2017, at a CAGR ...

Atherectomy Devices Market by Product, Application, End User - Global Forecasts To 2022

Atherectomy Devices Market: Global Forecasts until 2022

  • $ 5650
  • Industry report
  • November 2017
  • by MarketsandMarkets

The atherectomy devices market projected to grow at a CAGR of 6.1%The global atherectomy devices market is projected to reach USD 1.45 billion by 2022 from USD 1.08 billion in 2017, at a CAGR of 6.1%. ...

Blood Warmer Devices/Sample Warmer Market by Sample, End User, Region - Global Forecast to 2022

Blood Warmer Devices/Sample Warmer Market: Global Forecast until 2022

  • $ 5650
  • Industry report
  • November 2017
  • by MarketsandMarkets

Global blood warmer devices market projected to grow at a CAGR of 8.4% during the forecast periodThe blood warmer devices market is expected to reach USD 225.6 million by 2022 from USD 150.4 million in ...


ref:plp2016

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.